Shattuck Labs (STTK) Retained Earnings (2019 - 2026)
Shattuck Labs (STTK) posted quarterly Retained Earnings of -$445.3 million for Q1 2026, down 12.62% year-over-year from -$509.6 million in Q1 2025, and down 3.43% quarter-over-quarter from -$430.5 million in Q4 2025.
Analysis
Shattuck Labs (STTK) Retained Earnings (2019 - 2026) Analysis & Trends
Shattuck Labs (STTK) has reported Retained Earnings for 8 consecutive years, with -$445.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 12.62% year-over-year to -$445.3 million; the TTM figure through Mar 2026 stood at -$445.3 million (down 12.62% YoY), while the FY2025 annual figure was -$430.5 million, down 12.79% from the prior year.
- Retained Earnings declined to -$445.3 million in Q1 2026 per STTK's latest filing, from -$430.5 million in the prior quarter.
- Across five years, Retained Earnings topped out at $457.0 million in Q2 2024 and bottomed at -$445.3 million in Q1 2026.
- Historically, Retained Earnings has averaged -$99.5 million across 5 years, with a median of -$193.6 million in 2022.
- On a YoY basis, Retained Earnings climbed as much as 617643.24% in 2024 and fell as far as 5186400.0% in 2024.
- Shattuck Labs' Retained Earnings stood at -$877000.0 in 2022, then soared by 51526.0% to $451.0 million in 2023, then slumped by 184.64% to -$381.7 million in 2024, then declined by 12.79% to -$430.5 million in 2025, then retreated by 3.43% to -$445.3 million in 2026.
- Business Quant data shows STTK's Retained Earnings at -$445.3 million in Q1 2026, -$430.5 million in Q4 2025, and -$417.9 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.10 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -4.00 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.05 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -6.33 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 4.38 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Shattuck Labs | 885.09 Mn | 885.09 Mn | - | 671.64 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 671.64 Mn |
| Mar 31, 2026 | 541.12 Mn |
| Dec 31, 2025 | 512.91 Mn |
| Sep 30, 2025 | 511.17 Mn |
| Jun 30, 2025 | 464.89 Mn |
| Mar 31, 2025 | 463.00 Mn |
| Dec 31, 2024 | 461.34 Mn |
| Sep 30, 2024 | 459.56 Mn |
| Jun 30, 2024 | 456.98 Mn |
| Mar 31, 2024 | 453.64 Mn |
| Dec 31, 2023 | 451.01 Mn |
| Sep 30, 2023 | 401.39 Mn |
| Jun 30, 2023 | 399.61 Mn |
| Mar 31, 2023 | 397.72 Mn |
| Dec 31, 2022 | 396.04 Mn |
| Sep 30, 2022 | 394.35 Mn |
| Jun 30, 2022 | 392.60 Mn |
| Mar 31, 2022 | 391.06 Mn |
| Dec 31, 2021 | 389.41 Mn |
| Sep 30, 2021 | 387.90 Mn |